Partners

Corporate Venture Innovation.

You hold Capital. Diligence keeps returning the same verdict — the thesis is fine and the execution is not. We supply the read that names the gap, and the build capacity to close it.

The situation

The problem is rarely the market.

A portfolio company misses plan, and the board conversation defaults to hiring or runway. More often the venture is operating at the wrong stage — a Define-stage company behaving as though it is at Market, spending accordingly.

That is a diagnosable condition, and it is cheaper to name it than to fund around it for two more quarters.

What we supply

Diligence support and portfolio capacity.

01Technical diligenceAn honest read on architecture, AI claims and what production would actually cost.
02Stage diagnosisStuck-to-Scale applied pre-investment or post-, with the evidence attached.
03Portfolio interventionsFixed-scope engagements against the specific foundation a company is missing.
04Brand and product rescueWhere the product is sound and nothing about it reads that way.
05Corporate venture buildsNew ventures built alongside an internal team, with a real end date.
06Board-ready written readsShort, defensible, and free of consultant hedging.
How it runs

Read first, build only if warranted.

01
Brief
What the company claims, what the numbers say, and what the board is worried about.
Days
02
Diagnosis
One document, one conclusion, delivered to whoever you decide should see it.
2 weeks
03
Decide
Sometimes the recommendation is no further spend. We put that in writing too.
Session
04
Engagement
If a build is warranted: fixed scope, fixed end date, run with the founding team.
Scoped
Commercials

Structured for a fund, not a client.

01Per-diligence feeA fixed number per technical read, quoted before we start.
02Portfolio ratePreferential pricing across companies in the same fund.
03Equity-for-buildWhere the company is cash-constrained and the fund prefers not to bridge.
04No success theatreWe are not paid more for recommending a build.
The guarantees

What we will not do.

We do not soften a read for the party paying for it, and we do not take founder-side work that would conflict with a diligence engagement on the same company.

Roughly a third of our diagnoses conclude that no engagement should follow. That number is why the read is worth anything.

Yes — technical and product diligence, delivered on your timeline, in a form a partner meeting can use.

That is your call, and we recommend transparency: the read is more useful when the team can act on it.

Not cash. We invest build capacity against equity where the structure suits everyone.

Typically two weeks. Compressed timelines are possible; we will say what gets lost.

White-label

Name the gap before the next bridge.

Send us the company and the concern — the read comes back as one document and one conclusion.

Talk to the studio